human growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The clearance rate, or the rate at which the carrier protein is broken down, for GHBP alone is much faster than when it is bound to its ligand. Additionally, current literature provides evidence that the carrier-protein prolongs the half-life of growth hormone through its binding with the ligand. One purpose of GHBP can be inferred: to maintain the level of GH in the blood, as roughly half of its concentration is complexed with GHBP. Yet this could be confounded by the fact that GH binding to GHBP prevents the ligand from binding to GHR and ultimately proteolytic activity. Another function is that GHBP displays competitive inhibition for GH against the GHR receptor. Studies elucidate another aspect of GHBP physiological role: The proteolytic cleavage activity that forms GHBP ultimately regulates GHR production in humans as well as rats. If there is low GHBP concentration then there are high levels of GHR expression. Conversely, high levels of GHBP protein show negative correlation with levels of growth hormone receptor expression.
Aesculin (C21H24O13), occurring in horse-chestnut and California buckeye, and daphnin, occurring in Daphne alpina, are isomeric; the former hydrolyzes to glucose and aesculetin (C9H6O4 — 6,7-dihydroxycoumarin), the latter to glucose and daphnetin (7,8-dihydroxycoumarin). Fraxin, occurring in Fraxinus excelsior, hydrolyzes to glucose and fraxetin (also known as 7,8-dihydroxy-6-methoxycoumarin) Flavone or benzo-7-pyrone derivatives are numerous; in many cases they (or the non-sugar part of the molecule) are vegetable dyes. Rhamnetin, a splitting product of the glucosides of Rhamnus, is monomethyl quercetin; fisetin, from Rhus cotinus, is monoxyquercetin; chrysin is phenyl-dihydroxybenzopyrone. Saponarin, a glucoside found in Saponaria officinalis, is a related compound. Strophanthin is the name given to two different compounds, g-strophanthin (ouabain) obtained from Strophanthus gratus and k-strophanthin from Stroph. kombé.
=== 2006 === 13 March Beating Bird Flu, the May 1997 Hong Kong outbreak of H5N1 bird flu; Dutch virologist Ab Osterhaus at Erasmus MC in Rotterdam thought that the flu outbreak came from poultry markets; in January 2004 another bigger outbreak, 34 caught the virus but 25 died; Neil Ferguson of Imperial College; virologist John Oxford of the Royal London Hospital; virologist Chris Smith (The Naked Scientists) of the University of Cambridge; Alan Hay of the National Institute of Health Research; James Niven in Manchester in 1919, and the death rate was highest from ages 25 to 34; cyanosis occurred; historian Douglas Gill, and the British Army transit camp at Étaples, a possible source of the outbreak, where purulent bronchitis started in December 1916; the Armed Forces Institute of Pathology, where pathologist Jeffery Taubenberger sequenced the 1919 virus, which affected hemagglutinin receptors; the virus DNA had eight genes, which made ten proteins; virologist Terrence Tumpey at CDC Atlanta, who tested the 1919 virus on laboratory mice, where he found that neuraminidase helped the virus propagate; in the 1919 virus; the immune system could not recognise the 1919 virus sufficiently, and a cytokine storm occurred, which paradoxically happened most with people with the best immune systems, not older people; Neil Ferguson believed that a world pandemic would take two to three months to spread around the world, and would take 50 days to reach a peak in the UK, with one million cases per day.
NESHAP: Listed as a Hazardous Air Pollutant (HAP) Comprehensive Environmental Response, Compensation, and Liability Act: Reportable Quantity (RQ) = 100 lb Emergency Planning and Community Right-To-Know Act, EPA's Toxics Release Inventory: A listed substance subject to RCRA reporting requirements RCRA Listed Hazardous Waste: substance - U238
Tractor Supply Company became the first general merchandise retailer to offer same-day delivery from every store in April 2020 through Roadie. In September 2021, UPS entered an agreement to acquire Roadie for an undisclosed amount. The transaction was expected to close in the fourth quarter of 2021. Roadies, which at the time reported having 200,000 operators serving over 20,000 ZIP Codes, was expected to continue operations under its name as a separate company with no transfer of packages between the UPS and Roadies networks. The relationship between the companies goes back several years with UPS being an early investor. Earlier in 2021, UPS had begun a pilot program testing same-day deliveries via Roadies.
Sources: en.wikipedia.org
DiCaprio has mentioned growing up poor in a neighborhood plagued with prostitution, crime and violence. He was raised Catholic. DiCaprio attended the Los Angeles Center for Enriched Studies for four years and later Seeds Elementary School. He enrolled at John Marshall High School, but disliked public school and wanted to audition for acting jobs instead. He decided to drop out of high school, and later earned a general equivalency diploma (GED). As a child, DiCaprio wanted to become either an actor or a marine biologist. He chose to pursue acting because he enjoyed imitating people and impersonating characters, and liked seeing people's reactions to his impressions. According to DiCaprio, his interest in performing began at the age of two, when he went onstage at a performance festival and danced spontaneously to a positive response from the crowd. He was also motivated to learn acting when his stepbrother's appearance in a television commercial earned him $50,000. DiCaprio has said in interviews that his first television appearance was in the children's series Romper Room, and that he was dismissed from the show for being disruptive. The show's host has denied that any children were removed from the show in this way. At age 11, DiCaprio almost quit acting to pursue breakdancing, after winning second place in a breakdancing competition in his mother's native Germany. Starting at age 14, he appeared in several commercials for Matchbox cars, which he calls his first role. DiCaprio also appeared in commercials for Kraft Singles, Bubble Yum, and Apple Jacks.
=== Anti-human globulin cross-matching === The AHG crossmatch is done by incubating the recipient serum/plasma with the donor's red blood cells and adding anti-human globulin. It is essentially an indirect Coomb's test. It is also called "full cross-matching", "IAT cross-matching" and "Coomb's cross-matching".
=== Semiconductors === Semiconductor intellectual property, a business model for licensing intellectual property Single in-line package, for packaging electronic components System in package, chip technology, also known as a chip stack multi-chip module Silicon photonics, silicon semiconductor used as an optical medium
Severe respiratory instability Acute psychiatric instability Uncontrolled suicide risk Diagnosed non-nicotine substance abuse QTc intervals longer than 500 milliseconds if prescribed methadone Acute diversion of controlled substances Intolerance from previous trial use with specific opioids Serious adverse effects or lack of efficacy
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.